NCT01964924 - Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 2, 2013

Primary Completion Date

January 20, 2017

Study Completion Date

April 23, 2018

Conditions

Estrogen Receptor NegativeHER2/Neu NegativeInvasive Breast CarcinomaProgesterone Receptor NegativeRecurrent Breast CarcinomaStage IV Breast CancerTriple-Negative Breast Carcinoma

Interventions

DRUG

Akt Inhibitor GSK2141795

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Trametinib

Given PO

Trial Locations (8)

14263

Roswell Park Cancer Institute, Buffalo

20007

MedStar Georgetown University Hospital, Washington D.C.

23298

Virginia Commonwealth University/Massey Cancer Center, Richmond

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

33612

Moffitt Cancer Center, Tampa

43210

Ohio State University Comprehensive Cancer Center, Columbus

44106

Case Western Reserve University, Cleveland

44195

Cleveland Clinic Foundation, Cleveland